Metastatic Breast Cancer | A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
Metastatic Breast Cancer research study
What is the primary objective of this study?
Comparing Docetaxel Plus Fulvestrant With Docetaxel in Patients With Metastatic Breast Cancer
Who is eligible to participate?
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Metastatic Breast Cancer
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:Docetaxel75mg/m2 D2 every 21 days
Drug:Fulvestrant500mg D1, D15, D29, D57, every 28 days later
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Docetaxel Plus FulvestrantDocetaxel:75mg/m2 D2 every 21 days
Fulvestrant:500mg D1, D15, D29, D57, every 28 days later
DocetaxelDocetaxel:75mg/m2 D2 every 21 days
Start Date: April 2014
Completed Date: July 2017
Phase: Phase 2
Primary Outcome: Progression Free Survival
Secondary Outcome: Overall Response Rate
Study sponsors, principal investigator, and references
Principal Investigator: Xichun Hu, MD, PhD
Lead Sponsor: Fudan University